{"id":184924,"date":"2024-03-11T14:25:08","date_gmt":"2024-03-11T19:25:08","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/03\/daratumumab-plus-standard-therapy-for-multiple-myeloma"},"modified":"2024-03-11T14:25:08","modified_gmt":"2024-03-11T19:25:08","slug":"daratumumab-plus-standard-therapy-for-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/03\/daratumumab-plus-standard-therapy-for-multiple-myeloma","title":{"rendered":"Daratumumab Plus Standard Therapy for Multiple Myeloma"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/daratumumab-plus-standard-therapy-for-multiple-myeloma2.jpg\"><\/a><\/p>\n<p>People in the daratumumab group who stayed MRD negative for at least a year were able to stop taking daratumumab as maintenance therapy and remained cancer free. That\u2019s important, Dr. Sonneveld said, because taking fewer drugs long-term for maintenance therapy often translates to a better well-being and quality of life.<\/p>\n<p>Adding daratumumab to the standard treatment resulted in a nearly 60% drop in the risk of cancer progression or death (<a class=\"\" data-glossary-id=\"CDR0000618612\" href=\"https:\/\/www.cancer.gov\/Common\/PopUps\/popDefinition.aspx?id=CDR0000618612&version=Patient&language=en\">hazard ratio<\/a> of 0.42), the researchers determined.<\/p>\n<p>The magnitude of that change is \u201cunprecedented in these kinds of phase 3 trials [for] multiple myeloma,\u201d Dr. Sonneveld said.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>People in the daratumumab group who stayed MRD negative for at least a year were able to stop taking daratumumab as maintenance therapy and remained cancer free. That\u2019s important, Dr. Sonneveld said, because taking fewer drugs long-term for maintenance therapy often translates to a better well-being and quality of life. Adding daratumumab to the standard [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-184924","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/184924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=184924"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/184924\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=184924"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=184924"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=184924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}